Literature DB >> 32219702

The role of ErbB4 in cancer.

Vincent F M Segers1,2, Lindsey Dugaucquier3, Eline Feyen3, Hadis Shakeri3, Gilles W De Keulenaer3,4.   

Abstract

BACKGROUND: The epidermal growth factor receptor family consists of four members, ErbB1 (epidermal growth factor receptor-1), ErbB2, ErbB3, and ErbB4, which all have been found to play important roles in tumor development. ErbB4 appears to be unique among these receptors, because it is the only member with growth inhibiting properties. ErbB4 plays well-defined roles in normal tissue development, in particular the heart, the nervous system, and the mammary gland system. In recent years, information on the role of ErbB4 in a number of tumors has emerged and its general direction points towards a tumor suppressor role for ErbB4. However, there are some controversies and conflicting data, warranting a review on this topic.
CONCLUSIONS: Here, we discuss the role of ErbB4 in normal physiology and in breast, lung, colorectal, gastric, pancreatic, prostate, bladder, and brain cancers, as well as in hepatocellular carcinoma, cholangiocarcinoma, and melanoma. Understanding the role of ErbB4 in cancer is not only important for the treatment of tumors, but also for the treatment of other disorders in which ErbB4 plays a major role, e.g. cardiovascular disease.

Entities:  

Keywords:  ErbB4; cancer biology; cell growth; neuregulin-1

Mesh:

Substances:

Year:  2020        PMID: 32219702     DOI: 10.1007/s13402-020-00499-4

Source DB:  PubMed          Journal:  Cell Oncol (Dordr)        ISSN: 2211-3428            Impact factor:   6.730


  17 in total

1.  Neuregulin 4 suppresses NASH-HCC development by restraining tumor-prone liver microenvironment.

Authors:  Peng Zhang; Zhimin Chen; Henry Kuang; Tongyu Liu; Jiaqiang Zhu; Linkang Zhou; Qiuyu Wang; Xuelian Xiong; Ziyi Meng; Xiaoxue Qiu; Ramiah Jacks; Lu Liu; Siming Li; Carey N Lumeng; Qing Li; Xiang Zhou; Jiandie D Lin
Journal:  Cell Metab       Date:  2022-08-15       Impact factor: 31.373

Review 2.  The Mechanism of Long Non-coding RNA in Cancer Radioresistance/Radiosensitivity: A Systematic Review.

Authors:  Wenhan Wu; Shijian Zhang; Jia He
Journal:  Front Pharmacol       Date:  2022-05-05       Impact factor: 5.988

3.  Validation of a Patient-Derived Xenograft Model for Cervical Cancer Based on Genomic and Phenotypic Characterization.

Authors:  Shunsuke Miyamoto; Tomohito Tanaka; Kensuke Hirosuna; Ruri Nishie; Shoko Ueda; Sousuke Hashida; Shinichi Terada; Hiromi Konishi; Yuhei Kogata; Kohei Taniguchi; Kazumasa Komura; Masahide Ohmichi
Journal:  Cancers (Basel)       Date:  2022-06-16       Impact factor: 6.575

4.  Association of ERBB4 genetic polymorphism with the risk and prognosis of non-small cell lung cancer in Chinese Han population: A population-based case-control study.

Authors:  Wan-Ping Wang; Hai-Bo Bian; Xia-Zhen Wang; Liang Liu; Ding Wei
Journal:  Medicine (Baltimore)       Date:  2021-05-14       Impact factor: 1.889

Review 5.  PET and SPECT Imaging of the EGFR Family (RTK Class I) in Oncology.

Authors:  Sara S Rinne; Anna Orlova; Vladimir Tolmachev
Journal:  Int J Mol Sci       Date:  2021-04-01       Impact factor: 5.923

6.  The expression and prognostic value of the epidermal growth factor receptor family in glioma.

Authors:  Bin Xu; Zhengyuan Huo; Hui Huang; Wei Ji; Zheng Bian; Jiantong Jiao; Jun Sun; Junfei Shao
Journal:  BMC Cancer       Date:  2021-04-23       Impact factor: 4.430

7.  The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.

Authors:  Xilin Hu; Hanlin Xu; Qianwen Xue; Ruran Wen; Wenjie Jiao; Kaihua Tian
Journal:  Mol Med       Date:  2021-10-07       Impact factor: 6.354

Review 8.  A Review of HER4 (ErbB4) Kinase, Its Impact on Cancer, and Its Inhibitors.

Authors:  Mohammed I El-Gamal; Nada H Mewafi; Nada E Abdelmotteleb; Minnatullah A Emara; Hamadeh Tarazi; Rawan M Sbenati; Moustafa M Madkour; Seyed-Omar Zaraei; Afnan I Shahin; Hanan S Anbar
Journal:  Molecules       Date:  2021-12-05       Impact factor: 4.411

9.  Profile of Basal Cell Carcinoma Mutations and Copy Number Alterations - Focus on Gene-Associated Noncoding Variants.

Authors:  Paulina Maria Nawrocka; Paulina Galka-Marciniak; Martyna Olga Urbanek-Trzeciak; Ilamathi M-Thirusenthilarasan; Natalia Szostak; Anna Philips; Laura Susok; Michael Sand; Piotr Kozlowski
Journal:  Front Oncol       Date:  2021-11-25       Impact factor: 6.244

10.  Efficient representations of tumor diversity with paired DNA-RNA aberrations.

Authors:  Qian Ke; Wikum Dinalankara; Laurent Younes; Donald Geman; Luigi Marchionni
Journal:  PLoS Comput Biol       Date:  2021-06-11       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.